Literature DB >> 15014608

A Review of the Diagnosis, Pharmacologic Treatment, and Economic Aspects of Anxiety Disorders.

Steven R. Arikian1, Jack M. Gorman.   

Abstract

As many as 1 in 4 Americans will experience an anxiety disorder at some point in their lives, and many will also suffer the depression, substance abuse, distressing physical signs, and socioeconomic problems that often accompany these disorders when left untreated. Anxiety disorders can be detected using simple screening tools in the physician's office. Early and effective treatment with appropriate medication can significantly reduce the psychic and physical symptoms of anxiety, lowering the overall costs of the disorder to the health care system and society. Many drugs offer safe and effective relief of anxiety symptoms with few side effects or drug-drug interactions, and some offer symptomatic relief within 1 to 2 weeks.

Entities:  

Year:  2001        PMID: 15014608      PMCID: PMC181171          DOI: 10.4088/pcc.v03n0302

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN: 1523-5998


  47 in total

Review 1.  A treatment algorithm for the management of anxiety in primary care practice.

Authors:  R E Hales; D A Hilty; M G Wise
Journal:  J Clin Psychiatry       Date:  1997       Impact factor: 4.384

Review 2.  The role of SSRIs in panic disorder.

Authors:  D V Sheehan; K Harnett-Sheehan
Journal:  J Clin Psychiatry       Date:  1996       Impact factor: 4.384

Review 3.  Tricyclic therapy of the DSM-III anxiety disorders: a review with implications for further research.

Authors:  M R Liebowitz; A J Fyer; J M Gorman; R B Campeas; D P Sandberg; E Hollander; L A Papp; D F Klein
Journal:  J Psychiatr Res       Date:  1988       Impact factor: 4.791

4.  The nature and prevalence of anxiety disorders in primary care.

Authors:  L G Nisenson; C M Pepper; T L Schwenk; J C Coyne
Journal:  Gen Hosp Psychiatry       Date:  1998-01       Impact factor: 3.238

Review 5.  Diagnostic dilemmas presented by patients with anxiety and depression.

Authors:  R J Goldberg
Journal:  Am J Med       Date:  1995-03       Impact factor: 4.965

6.  Clomipramine in the treatment of patients with obsessive-compulsive disorder. The Clomipramine Collaborative Study Group.

Authors: 
Journal:  Arch Gen Psychiatry       Date:  1991-08

Review 7.  Rapid diagnosis and treatment of anxiety and depression in primary care: the somatizing patient.

Authors:  O L Baughman
Journal:  J Fam Pract       Date:  1994-10       Impact factor: 0.493

8.  Detecting anxiety and depression in general medical settings.

Authors:  D Goldberg; K Bridges; P Duncan-Jones; D Grayson
Journal:  BMJ       Date:  1988-10-08

9.  The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services.

Authors:  D A Regier; W E Narrow; D S Rae; R W Manderscheid; B Z Locke; F K Goodwin
Journal:  Arch Gen Psychiatry       Date:  1993-02

10.  The social costs of anxiety disorders.

Authors:  A C Leon; L Portera; M M Weissman
Journal:  Br J Psychiatry Suppl       Date:  1995-04
View more
  7 in total

Review 1.  Was Hawan Designed to Fight Anxiety-Scientific Evidences?

Authors:  R K Romana; A Sharma; V Gupta; R Kaur; S Kumar; P Bansal
Journal:  J Relig Health       Date:  2020-02

2.  Association between sudden sensorineural hearing loss and anxiety disorder: a population-based study.

Authors:  Shiu-Dong Chung; Shih-Han Hung; Herng-Ching Lin; Jau-Jiuan Sheu
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-08-13       Impact factor: 2.503

3.  Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders.

Authors:  David V Sheehan; Matthew S Keene; Michael Eaddy; Stan Krulewicz; John E Kraus; David J Carpenter
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

4.  Diagnosis and Treatment Procedures for Patients With Anxiety Disorders by the Psychiatric Consultation Liaison Service in a General Hospital in Germany: A Retrospective Analysis.

Authors:  Christina Anderson; Deborah Tauch; Arnim Quante
Journal:  Prim Care Companion CNS Disord       Date:  2015-10-08

5.  The Use of Antidepressants, Anxiolytics, Sedatives and Hypnotics in Europe: Focusing on Mental Health Care in Portugal and Prescribing in Older Patients.

Authors:  Marta Estrela; Maria Teresa Herdeiro; Pedro Lopes Ferreira; Fátima Roque
Journal:  Int J Environ Res Public Health       Date:  2020-11-19       Impact factor: 3.390

6.  The prevalence of anxiety symptoms and disorders among ophthalmic disease patients.

Authors:  Zulvikar Syambani Ulhaq; Gita Vita Soraya; Nadia Artha Dewi; Lely Retno Wulandari
Journal:  Ther Adv Ophthalmol       Date:  2022-04-19

7.  Psychobiotics Regulate the Anxiety Symptoms in Carriers of Allele A of IL-1β Gene: A Randomized, Placebo-Controlled Clinical Trial.

Authors:  P Gualtieri; M Marchetti; G Cioccoloni; A De Lorenzo; L Romano; A Cammarano; C Colica; R Condò; L Di Renzo
Journal:  Mediators Inflamm       Date:  2020-01-07       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.